HOLON, Israel,Oct 2, 2023/ PUBLIC RELATIONSNew swire/– Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy firm and a leader in computational target exploration, today revealed that the Japanese Patent Office has actually approved Compugen a patent for dealing with cancer with a triple combination of any anti- PVRIG antibody with any anti-TIGIT and anti-PD-1 antibody.
Japanese patentNo JP7348072B2, entitled “Triple Combination Antibodies Therapies” increases formerly released patent in Japan by broadening and securing Compugen’s separated and leading triple clog of the DNAM-1 axis with any anti-PVRIG in combination with any anti-TIGIT and anti-PD-1 antibody.
“We are delighted to strengthen our patent portfolio supporting our leadership in blocking three pathways of the DNAM-1 axis, PVRIG, TIGIT and PD-1”, claimed Anat Cohen-Dayag,Ph D., President, and Chief …